Bausch + Lomb (BLCO) Competitors $12.96 -1.39 (-9.66%) Closing price 04/3/2025 03:58 PM EasternExtended Trading$12.00 -0.96 (-7.43%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLCO vs. SOLV, SNN, PEN, STVN, GKOS, INSP, NARI, IRTC, SLNO, and PRCTShould you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inspire Medical Systems (INSP), Inari Medical (NARI), iRhythm Technologies (IRTC), Soleno Therapeutics (SLNO), and PROCEPT BioRobotics (PRCT). These companies are all part of the "medical equipment" industry. Bausch + Lomb vs. Solventum Smith & Nephew Penumbra Stevanato Group Glaukos Inspire Medical Systems Inari Medical iRhythm Technologies Soleno Therapeutics PROCEPT BioRobotics Solventum (NYSE:SOLV) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment, community ranking and profitability. Does the MarketBeat Community favor SOLV or BLCO? Bausch + Lomb received 37 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 40.86% of users gave Bausch + Lomb an outperform vote while only 4.17% of users gave Solventum an outperform vote. CompanyUnderperformOutperformSolventumOutperform Votes14.17%Underperform Votes2395.83% Bausch + LombOutperform Votes3840.86% Underperform Votes5559.14% Which has better valuation & earnings, SOLV or BLCO? Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolventum$8.25B1.48$475.72M$2.7525.59Bausch + Lomb$4.79B0.95-$317M-$0.91-14.25 Does the media favor SOLV or BLCO? In the previous week, Solventum had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 16 mentions for Solventum and 13 mentions for Bausch + Lomb. Solventum's average media sentiment score of 0.95 beat Bausch + Lomb's score of 0.11 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 10 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 2 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer SOLV or BLCO? Solventum presently has a consensus target price of $79.86, suggesting a potential upside of 13.46%. Bausch + Lomb has a consensus target price of $18.91, suggesting a potential upside of 45.86%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Solventum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solventum 1 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Bausch + Lomb 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do insiders & institutionals believe in SOLV or BLCO? 11.1% of Bausch + Lomb shares are owned by institutional investors. 0.1% of Solventum shares are owned by insiders. Comparatively, 0.2% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is SOLV or BLCO more profitable? Solventum has a net margin of 0.00% compared to Bausch + Lomb's net margin of -6.62%. Bausch + Lomb's return on equity of 3.35% beat Solventum's return on equity.Company Net Margins Return on Equity Return on Assets SolventumN/A N/A N/A Bausch + Lomb -6.62%3.35%1.66% SummaryBausch + Lomb beats Solventum on 9 of the 17 factors compared between the two stocks. Remove Ads Get Bausch + Lomb News Delivered to You Automatically Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLCO vs. The Competition Export to ExcelMetricBausch + LombOphthalmic goods IndustryMedical SectorNYSE ExchangeMarket Cap$4.57B$10.61B$5.53B$18.93BDividend YieldN/A0.96%4.86%3.79%P/E Ratio-14.2534.2423.2231.59Price / Sales0.952.84363.0825.45Price / Cash8.4114.5338.1617.54Price / Book0.702.366.494.36Net Income-$317M$224.27M$3.21B$1.02B7 Day Performance-8.54%-11.54%-4.91%-3.87%1 Month Performance-18.29%-17.62%-0.08%-4.82%1 Year Performance-19.83%-27.41%6.40%0.29% Bausch + Lomb Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLCOBausch + Lomb3.796 of 5 stars$12.96-9.7%$18.91+45.9%-21.4%$4.57B$4.79B-14.2512,500Analyst ForecastNews CoverageSOLVSolventum1.4076 of 5 stars$76.02+1.7%$79.86+5.0%+10.2%$13.15B$8.25B27.6422,000SNNSmith & Nephew2.783 of 5 stars$28.39+1.2%$27.00-4.9%+13.3%$12.41B$5.81B13.1420,100Positive NewsPENPenumbra4.3293 of 5 stars$267.84+0.1%$294.47+9.9%+26.8%$10.32B$1.19B787.773,900Insider TradeGap DownSTVNStevanato Group1.6672 of 5 stars€20.37+0.4%N/A-32.6%$6.17B$1.10B43.344,650Positive NewsGKOSGlaukos3.9379 of 5 stars$98.49-3.4%$163.25+65.8%-7.9%$5.57B$383.48M-34.32780News CoveragePositive NewsGap DownINSPInspire Medical Systems4.848 of 5 stars$159.60+1.5%$226.70+42.0%-29.0%$4.75B$802.80M92.261,246Positive NewsNARIInari Medical0.9962 of 5 stars$79.97flat$68.00-15.0%N/A$4.68B$493.63M-59.24800IRTCiRhythm Technologies1.9571 of 5 stars$104.68-0.3%$119.73+14.4%-1.5%$3.29B$591.84M-28.761,790News CoveragePositive NewsGap DownSLNOSoleno Therapeutics4.5587 of 5 stars$71.45-0.8%$98.86+38.4%+72.8%$3.28BN/A-21.5230Insider TradeAnalyst RevisionGap DownHigh Trading VolumePRCTPROCEPT BioRobotics2.669 of 5 stars$58.26-3.0%$94.29+61.8%+17.7%$3.19B$224.50M-29.88430News CoverageGap Down Remove Ads Related Companies and Tools Related Companies Solventum Competitors Smith & Nephew Competitors Penumbra Competitors Stevanato Group Competitors Glaukos Competitors Inspire Medical Systems Competitors Inari Medical Competitors iRhythm Technologies Competitors Soleno Therapeutics Competitors PROCEPT BioRobotics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BLCO) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bausch + Lomb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BLCO Stock Free BLCO Stock Alerts